MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/art.42417

Медицинская библиотека · Arthritis & rheumatology (Hoboken, N.J.) · 2023

Criteria for Hyperinflammation Developing in COVID-19: Analysis of 2 Cohorts From Different Periods of the Pandemic.

Amikishiyev Shirkhan, Gunver M Guven, Bektas Murat, Aghamuradov Sarvan, Ince Burak, Koca Nevzat, Torun Ege Sinan, Aliyeva Numune, Sari Selma, Cetin Cigdem, Yalcin-Dulundu Banu C, Deniz Rabia, Kemik Fatih, Agargun Besim Fazil, Gulseren Ubeyde Ayse, Besisik Beliz, Alkan Onur, Bagriacik Ceren, Tor Yavuz B, Senkal Naci, Catma Yunus, Durak Gorkem, Mese Sevim, Agacfidan Ali, Kose Murat, Erelel Mustafa, Cagatay A Atahan, Simsek-Yavuz Serap, Kalayoglu-Besisik Sevgi, Esen Figen, Gül Ahmet

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Hyperinflammation (HI) that develops in week 2 of COVID-19 contributes to a worse outcome. Because week 2 laboratory findings can be relatively mild, the available criteria for classification of hemophagocytic lymphohistiocytosis or macrophage activation syndrome are not helpful.

METHODS

Our study included a discovery cohort of patients from Turkey with symptomatic COVID-19 who were followed up while hospitalized during the initial wave and a replication cohort of hospitalized patients from a later period, all of whom required oxygen support and received glucocorticoids. Diagnosis of HI was made by an expert panel; most patients with COVID-19-associated HI (HIC) received tocilizumab or anakinra. Clinical and laboratory data from start day of treatment with tocilizumab or anakinra in HIC patients were compared with the data from day 5-6 in patients without HIC. Values maximizing the sensitivity and specificity of each parameter were calculated to determine criteria items.

RESULTS

The discovery cohort included 685 patients, and the replication cohort included 156 patients, with 150 and 61 patients receiving treatment for HI, respectively. Mortality rate in HI patients in the discovery cohort (23.3%) was higher than the rate in patients without HI (3.7%) and the rate in patients in the overall replication cohort (10.3%). The 12-item criteria that we developed for HIC showed that a score of 35 provided 85.3% sensitivity and 81.7% specificity for identification of HIC. In the replication cohort, the same criteria resulted in 90.0% sensitivity for HIC; however, lower specificity values were observed because of the inclusion of milder cases of HIC responding only to glucocorticoids.

CONCLUSION

The use of the 12-item criteria for HIC can better define patients with HIC with reasonable sensitivity and specificity and enables an earlier treatment start.

Для цитирования: Amikishiyev Shirkhan, Gunver M Guven, Bektas Murat, Aghamuradov Sarvan, Ince Burak, Koca Nevzat, Torun Ege Sinan, Aliyeva Numune, Sari Selma, Cetin Cigdem, Yalcin-Dulundu Banu C, Deniz Rabia, Kemik Fatih, Agargun Besim Fazil, Gulseren Ubeyde Ayse, Besisik Beliz, Alkan Onur, Bagriacik Ceren, Tor Yavuz B, Senkal Naci, Catma Yunus, Durak Gorkem, Mese Sevim, Agacfidan Ali, Kose Murat, Erelel Mustafa, Cagatay A Atahan, Simsek-Yavuz Serap, Kalayoglu-Besisik Sevgi, Esen Figen, Gül Ahmet. Criteria for Hyperinflammation Developing in COVID-19: Analysis of 2 Cohorts From Different Periods of the Pandemic.. Arthritis & rheumatology (Hoboken, N.J.). 2023. DOI: 10.1002/art.42417.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.